ClinicalTrials.gg
RecruitingNCT05851534PROMISE-PUpdated Oct 19, 2026

Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas

An interventional study of Preoperative optimisation program in Prehabilitation, Pancreas Cancer and Surgery, sponsored by Maastricht University Medical Center. Recruiting at 13 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 19, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,575
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Pancreatic Neoplasms with a site in Netherlands — 22 open to participants now, 34 under way, 6 of them phase 3. Pancreatic Neoplasms · Netherlands.

Planned enrollment
2nd of 89
2,575 · median 97
Started
2024
with 7 others
No phase
26 of 106
6 open now
Primary completion
2027-09
later than 22 of 33 live
Registered
84th of 106
by date
Lead sponsor
5 of 106
Maastricht University Medical Center

Among the 106 studies in Pancreatic Neoplasms with a site in Netherlands, this one is the 2nd largest by planned enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2024, is one of 26 with no phase, reaches primary completion later than 22 of the 33 other live ones, and was the 84th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 106 studies in Pancreatic Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Pancreatic Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors in patients with (suspected) pancreatic cancer will improve outcome. The main questions it will aim to answer are:

  1. Does a prehabilitation program improve the time to functional recovery after pancreatic surgery?
  2. Does a prehabilitation program lead to a reduction in the Comprehensive Complication Index after pancreatic surgery?
Read the detailed description

Background In the past, little attention has been given in the daily practice to the patient's condition before an operation. Recent studies have shown the benefit of preoperative optimisation programs. However, these studies consisted only of smaller studies and were mainly performed in patients who underwent colorectal surgery. Although promising, unfortunately, strong evidence to support the contribution of prehabilitation to optimize the functional outcome after surgery is still lacking and consequently it is not included in the Dutch basic health insurance package.

Objective To investigate whether implementation of a best practice program for preoperative optimisation of patients with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors (low (aerobic) fitness level, malnutrition, low psychological resilience, comorbidities (iron deficiency (anaemia), impaired glucose control and frailty), and intoxications (alcohol and smoking behaviour)) will improve the time to functional recovery.

Study design A nationwide stepped-wedge cluster randomized trial. In this design all participating centres will cross over from current practice to the best practice program, in a randomised order. At the end of the study, all centres will have implemented the best practice program.

Study population 13 centres performing major pancreatic surgery in the Netherlands collaborating within the Dutch Pancreatic Cancer Group (DPCG).

Intervention Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed. This program is based on findings in previous screening and prehabilitation programs, a national inventory of current preoperative care protocols and expert opinion. Consensus upon this program was reached with pancreatic surgeons from all centres of the DPCG. The final program was critically reviewed by the advisory committee of internationally respected experts in the field of prehabilitation and pancreatology.

Comparison Preoperative care according to current practice.

03

Conditions studied

  • Prehabilitation
  • Pancreas Cancer
  • Surgery
  • Postoperative Complications

Keywords

  • Prehabilitation
  • Pancreas
  • Preoperative optimisation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who are planned for a curative treatment with or without treatment and elective pancreatic resection in one of the centres of the Dutch Pancreatic Cancer Group (i.e. all centres performing major pancreatic surgery)

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • acute pancreatic resections (resection scheduled within two weeks)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2,575 participants (estimated)

Study arms

  • No intervention
    Standard care

    Receiving standard preoperative care

  • Experimental
    Best practice program

    Implementation of best practice preoperative optimisation program

    Behavioral: Preoperative optimisation program

Interventions

  • BehavioralPreoperative optimisation program

    Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed

06

What researchers measure

Primary outcomes

  1. Time to functional recovery

    Functional recovery is achieved when all of the following five criteria are met: a) restored level of mobility at the preoperative level, b) sufficient pain control with oral medication alone, c) ability to maintain at least 50% daily required energy intake, d) no intravenous fluid administration, and e) no clinical signs of infection.

    Time frame: On average 6-10 days

Secondary outcomes

  1. Comprehensive Complication Index (CCI)

    The CCI is calculated as the sum of all complications that are weighted for their severity, with a range from 0 to 100, whereby a higher score indicates presence of more complications and/or more severe complications.

    Time frame: 30 days postoperative

  2. Length of hospital stay

    Length of hospital stay of the primary admission, measured in days

    Time frame: On average 2 weeks postoperative

  3. Readmissions

    Readmissions within 30 days after discharge

    Time frame: 30 days after discharge of primary admission

  4. Postoperative complications

    Any postoperative complication

    Time frame: During primary admission, on average 14 weeks postoperative

  5. Incremental cost-effectiveness ratio (ICER)

    The difference in costs between standard care and best practice care divided by the difference in health benefits, measured in quality-adjusted life years (QALYs).

    Time frame: 1 year postoperative

  6. Evaluation of health status

    Reported health status measured with questionnaire EQ-5D-5L

    Time frame: At baseline, 3 months and 12 months postoperative

  7. Evaluation of quality of life for cancer patients

    Reported quality of life measured with questionnaire EORTC QLQ-C30

    Time frame: At baseline, 3 months and 12 months postoperative

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial will be shared, after deidentification upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 3 months and ending 5 years following article publication

Access criteria: Data will be available upon request. Request should be directed to marcel.den.dulk@mumc.nl.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
May 9, 2023
StartActual
Sep 2, 2024
Primary completionEst.
Sep 2, 2027
CompletionEst.
Sep 2, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Jeroen Bosch Hospital · 's-Hertogenbosch, Netherlands
Show 1 removed
  • Jeroen Bosch Hospital · Den Bosch, Netherlands
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • Jeroen Bosch Hospital · 's-Hertogenbosch, Netherlands
    Show 1 removed
    • Jeroen Bosch Hospital · Den Bosch, Netherlands
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05851534
Collaborators
Rising Tide Foundation
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Sep 2, 2024
Primary completion
Sep 2, 2027 (estimated)
Completion
Sep 2, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Marcel den Dulk, MD PhD
Contact
marcel.den.dulk@mumc.nl
+3143 3875492
Heleen Driessens, MD
Contact
h.driessens@umcg.nl
+316 83058108
Marcel den Dulk, MD PhD
principal investigator · Maastricht University Medical Center/ University Maastricht

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion